Insider · CIK 0001216917
Michael Bigham
Files at PRTK (Paratek Pharmaceuticals, Inc.), FLAC (Frazier Lifesciences Acquisition Corp). First filing Nov 1, 2022, latest Dec 22, 2022.
In brief
Michael Bigham files SEC Form 4 as chair and director at PRTK (Paratek Pharmaceuticals, Inc.), and also at FLAC (Frazier Lifesciences Acquisition Corp). Since Nov 1, 2022, Michael Bigham has reported 0 open-market buys worth $0 and 3 open-market sells worth $153k, the latest filed on Dec 22, 2022.
A track record needs three past buys with six months of prices behind them; Michael Bigham has 0, so none is measured yet.
The newest scored trade: sold $31k of PRTK on Dec 21, 2022, filed Dec 22, 2022, scored 13 (weak), under a 10b5-1 plan.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 13Weak | Paratek Pharmaceuticals, Inc. | $31k 15,750 shares | -1% | - | |
| 18Weak | Paratek Pharmaceuticals, Inc. | $101k 51,375 shares | -4% | - | |
| 8Weak | Paratek Pharmaceuticals, Inc. | $21k 6,000 shares | -0% | - |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 20, 2022 | PRTK Paratek Pharmaceuticals, Inc. | AGrant or award Common Stock | +45,000 | $0.00 | $0 | 1,225,452 | Dec 22, 2022 |
| Dec 21, 2022 | PRTK Paratek Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -15,750 | $1.99 | $31k | 1,209,702 | Dec 22, 2022 |
| Dec 12, 2022 | PRTK Paratek Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -19,484 | $1.98 | $39k | 1,212,343 | Dec 14, 2022 |
| Dec 13, 2022 | PRTK Paratek Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -31,891 | $1.96 | $63k | 1,180,452 | Dec 14, 2022 |
| Nov 22, 2022 | FLAC Frazier Lifesciences Acquisition Corp | MOption exercise Class B Ordinary Sharesderivative | -30,000 | - | - | 0 | Nov 23, 2022 |
| Oct 28, 2022 | PRTK Paratek Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -6,000 | $3.47 | $21k | 1,231,827 | Nov 1, 2022 |
| Oct 25, 2022 | PRTK Paratek Pharmaceuticals, Inc. | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 1,237,827 | Oct 27, 2022 |
Questions about Michael Bigham
Answered from the filings on this page, as of the latest one.
Is Michael Bigham buying or selling?
Not in the last 12 months. Michael Bigham's latest open-market trade on SEC Form 4 was sold $31k of PRTK on Dec 21, 2022.
How did Michael Bigham's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael Bigham has 0.
Where does Michael Bigham file Form 4?
Michael Bigham has filed Form 4 at PRTK (Paratek Pharmaceuticals, Inc.) as Exec. Chairman of the Board; FLAC (Frazier Lifesciences Acquisition Corp). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.